Amarantus Bioscience (OTCMKTS:AMBS) and BrightSpring Health Services (NASDAQ:BTSG) Head-To-Head Contrast

BrightSpring Health Services (NASDAQ:BTSG) and Amarantus Bioscience (OTCMKTS:AMBS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Volatility and Risk

BrightSpring Health Services has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares BrightSpring Health Services and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.55%	16.73%	5.24%
Amarantus Bioscience	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BrightSpring Health Services and Amarantus Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0	0	18	2	3.10
Amarantus Bioscience	0	0	0	0	0.00

BrightSpring Health Services currently has a consensus target price of $70.71, indicating a potential upside of 18.48%. Given BrightSpring Health Services’ stronger consensus rating and higher possible upside, equities analysts clearly believe BrightSpring Health Services is more favorable than Amarantus Bioscience.

Earnings and Valuation

This table compares BrightSpring Health Services and Amarantus Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91 billion	0.91	$190.67 million	$1.66	35.95
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

BrightSpring Health Services has higher revenue and earnings than Amarantus Bioscience.

Summary

BrightSpring Health Services beats Amarantus Bioscience on 9 of the 9 factors compared between the two stocks.

About BrightSpring Health Services

BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.